Cempra

Cempra is a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for the acute care and community settings to meet critical medical needs in the treatment of infectious diseases. The Company's lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, for the treatment of community-acquired bacterial pneumonia, or CABP, one of the most serious infections of the respiratory tract in adults and children, as well as for ophthalmic infections and other indications.

Revenue(FY, 2016)

$18 M

Market capitalization(2018-04-20)

$26.8 M

Type

Public

Chapel Hill, US

Founded

2006

Size (employees)

45 (est)

Website

cempra.com

Cempra was founded in 2006 and is headquartered in Chapel Hill, US

Report incorrect company information

Key People/Management at Cempra

Prabhavathi Fernandes

President & CEO

Mark Hahn

EVP & CFO

David Moore

EVP & CCO

Report incorrect company information

Cempra Office Locations

Cempra has an office in Chapel Hill

Chapel Hill, US (HQ)

360 6320 Quadrangle Dr

Show all (1)

Report incorrect company information

Cempra Financials and Metrics

Cempra Financials

Cempra's revenue was reported to be $18.02 m in FY, 2016 which is a 34% decrease from the previous period.

Summary

USD
Revenue (Q2, 2017)	860 k
Net income (Q2, 2017)	(12.3 m)
EBIT (Q2, 2017)	(12.3 m)
Market capitalization (20-Apr-2018)	26.8 m
Cash (30-Jun-2017)	187 m
EV	(148.2 m)

Cempra's current market capitalization is $26.8 m.

Income Statement

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Revenue	7.8 m	15.2 m	27.3 m	18 m
Revenue growth, %		95%	79%	(34%)
General and administrative expense	9.4 m	12.1 m	22.9 m	53.5 m
R&D expense	41.3 m	62.5 m	93.4 m	81.7 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Revenue	1.2 m	3.1 m	1.9 m	7.8 m	5.1 m	2.5 m	2.7 m	3.4 m	4 m	4.9 m	860 k
General and administrative expense	2.2 m	3.2 m	2.6 m	2.9 m	5.7 m	5.8 m	8.3 m	12 m	15 m	8.8 m	4.7 m
R&D expense	11.9 m	16.4 m	15.2 m	15.7 m	23.7 m	23.5 m	23.5 m	16 m	21.1 m	15.4 m	8.5 m
Operating expense total	14.1 m	19.6 m	17.8 m	18.5 m	29.4 m	29.4 m	31.9 m	28 m	36.1 m	27.7 m	13.2 m

show all

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Cash	96.5 m	99.1 m	153.8 m	231.6 m
Accounts Receivable		199.9 m
Inventories			7.5 m	13.4 m
Current Assets	98.5 m	104.9 m	162 m	238.3 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Cash	110.4 m	79.6 m	68.6 m	74.2 m	202.4 m	182 m	223.6 m	250.7 m	248.9 m	202.8 m	187 m
Current Assets	111.7 m	84.5 m	72.9 m	81.5 m	207.9 m	186.5 m	228.7 m	256.1 m	254.2 m	210.3 m	190.4 m
Total Assets	112.1 m	85 m	73.5 m	82 m	208.1 m	186.7 m	228.9 m	256.4 m	254.4 m	210.5 m	190.5 m
Accounts Payable	3.9 m	8.8 m	9.4 m	10.8 m	13.8 m	14.9 m	11.2 m	14.5 m	12.5 m	11.8 m	6.8 m

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Net Income	(45 m)	(61.6 m)	(91.1 m)	(118 m)
Depreciation and Amortization	39.6 k	76.3 k	69.2 k	51 k
Inventories	(617 k)	(1.2 m)	(153.6 m)	5.2 m
Accounts Payable	4.1 m	5.6 m	(2.3 m)	6 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Net Income	(28.2 m)	(17 m)	(33.4 m)	(44.8 m)	(42.4 m)	(70 m)	(29.4 m)	(54.2 m)	(86.5 m)	(22.9 m)	(35.2 m)
Depreciation and Amortization	21.5 k	14.5 k	29.8 k	44.9 k	39.5 k	54.4 k	14.9 k	30 k	40 k	9 k	15 k
Accounts Payable	1.7 m	2.5 m	3.1 m	4.5 m	1.9 m	3 m	1.6 m	4.9 m	2.9 m	(3.9 m)	(8.9 m)
Cash From Operating Activities	(18.6 m)	(16.9 m)	(30.8 m)	(35.9 m)	(37.3 m)	(59.5 m)	(24.2 m)	(41.9 m)	(71.3 m)	(27.2 m)	(41.5 m)